Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bolt Biotherapeutics, Inc.BOLT · Entity 8082 | Chief Scientific Officer | February 18, 2022 | February 24, 2022 |
| Whitehawk Therapeutics, Inc.WHWK · Entity 6074 | Chief Scientific Officer | September 15, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bolt Biotherapeutics, Inc.
Report date February 18, 2022 · Filed February 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.08 · Expires 2032-02-17 | Direct | 210,000 |
Reported balance
After 2022-02-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-18 · Grant · Acquired 210,000 · Balance 210,000 F1: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2022.
Whitehawk Therapeutics, Inc.
Report date September 15, 2026 · Filed September 18, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2036-09-15 | Direct | 85,887 |
Reported balance
After 2026-09-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 85,887 · Balance 85,887 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 85,887 |
Reported balance
After 2026-09-15 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2026-09-15 · Grant · Acquired 85,887 · Balance 85,887 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
F3: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Elevation Oncology, Inc.
Report date February 15, 2025 · Filed February 19, 2025
Section 16 reporting ended · disclosed 2025-02-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,223 |
Ending reported balance
After 2025-02-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-15 · Exercise / conversion · Acquired 9,375 · Balance 9,375 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2025-02-15 · Tax withholding · Disposed 4,152 · Balance 5,223 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 28,125 |
Reported balance
After 2025-02-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-15 · Exercise / conversion · Disposed 9,375 · Balance 28,125 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2: 25% of the RSUs vested on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3: The RSUs do not expire; they either vest or are canceled prior to the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2: 25% of the RSUs vested on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3: The RSUs do not expire; they either vest or are canceled prior to the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 18, 2026 20:43 UTC Amendment | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantRestricted Stock Units · Derivative | 85,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001821353-26-000007 · form4a-09182026_080955.xml · derivative · entry 2 Dornan David · CIK 0001821353 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,887 Underlying: Common Stock · 85,887 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3 · derivative.exercise_date: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. F3 · derivative.expiration_date: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 20:43 UTC Amendment | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 85,887 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001821353-26-000007 · form4a-09182026_080955.xml · derivative · entry 1 Dornan David · CIK 0001821353 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,887 Underlying: Common Stock · 85,887 shares Expires 2036-09-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:05 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantRestricted Stock Units · Derivative | 85,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001821353-26-000005 · form4-09152026_110942.xml · derivative · entry 2 Dornan David · CIK 0001821353 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,887 Underlying: Common Stock · 85,887 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean September 15, 2026. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 23:05 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 85,887 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001821353-26-000005 · form4-09152026_110942.xml · derivative · entry 1 Dornan David · CIK 0001821353 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,887 Underlying: Common Stock · 85,887 shares Expires 2036-09-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:22 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 282,340 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001821353-26-000003 · form4-04032026_100433.xml · derivative · entry 1 Dornan David · CIK 0001821353 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,340 Underlying: Common Stock · 282,340 shares Expires 2036-04-01 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2026. Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 23:11 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock Option (right to buy) · Derivative | 687,979 | $0.00 Strike: $2.31 | $0.00 |
DisclosureSEC source: 0001415889-25-006678 · form4-03042025_110311.xml · derivative · entry 1 Dornan David · CIK 0001821353 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 687,979 Underlying: Common Stock · 687,979 shares Expires 2035-03-04 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean February 18, 2025. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 16:15 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | Exercise / conversionRestricted Stock Unit · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004595 · form4-02192025_040201.xml · derivative · entry 3 Dornan David · CIK 0001821353 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 25% of the RSUs vested on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 16:15 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | Tax withholdingCommon Stock | 4,152 | $0.67 | $2,788.90 |
DisclosureSEC source: 0001415889-25-004595 · form4-02192025_040201.xml · nonDerivative · entry 2 Dornan David · CIK 0001821353 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,223 Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 16:15 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | Exercise / conversionCommon Stock | 9,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-004595 · form4-02192025_040201.xml · nonDerivative · entry 1 Dornan David · CIK 0001821353 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 16:52 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantRestricted Stock Unit · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004392 · form4-02202024_090212.xml · derivative · entry 2 Dornan David · CIK 0001821353 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs vest on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to the vesting date. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 16:52 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0001415889-24-004392 · form4-02202024_090212.xml · derivative · entry 1 Dornan David · CIK 0001821353 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2034-02-14 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 15, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 16:26 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001415889-23-002769 · form4-02172023_090219.xml · derivative · entry 1 Dornan David · CIK 0001821353 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2033-02-14 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 15, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 16:27 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001415889-23-000728 · form4-01102023_090138.xml · derivative · entry 1 Dornan David · CIK 0001821353 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2033-01-05 F1 · derivative.exercise_date: The stock option vested as to 25% of the total shares on January 6, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 17:46 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantEmployee Stock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001209191-22-019286 · doc4.xml · derivative · entry 1 Dornan David · CIK 0001821353 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2032-03-13 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on March 14, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date and is subject to acceleration in the event of a change in control of the Issuer. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 02:19 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 210,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000899243-22-007520 · doc4.xml · derivative · entry 1 Dornan David · CIK 0001821353 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2032-02-17 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2022. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 22:04 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008527 · doc4.xml · derivative · entry 1 Dornan David · CIK 0001821353 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2031-02-03 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/48th of the Shares will vest upon the Reporting Person completing each month of continuous service following February 4, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.